Program
Autologous Anti-CD19 CAR-T Cells CABA-201
Also written as “CABA-201” and “CABA-201 following preconditioning with fludarabine and cyclophosphamide”.
Its studies are mostly in Dermatomyositis · Myasthenia Gravis · Scleroderma, Systemic · Pemphigus · Lupus Nephritis, led by Cabaletta Bio.
Drug pageAutologous Anti-CD19 CAR-T Cells CABA-201: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cabaletta Bio | 65 open or running | phase 3since Nov 16, 2023 | Jun 2, 2020 | Jul 2028phase 3 · NCT06154252 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 2, 2020First study: phase 2 study in PemphigusFirst studyNCT04422912 · 40 planned · United States
- Oct 23, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT06121297 · 28 planned · United States, Canada, Spain
- Nov 16, 2023Phase 3 study in MyositisNCT06154252 · 74 planned · United States, Germany, Italy and more
- Mar 19, 2024Phase 3 study in Scleroderma, SystemicNCT06328777 · 37 planned · United States
- Mar 21, 2024Phase 2 study in Myasthenia GravisNCT06359041 · 24 planned · United States
- Apr 22, 2025Phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT07006805
Ahead
- Jul 2028Primary completion: phase 3 study in MyositisNCT06154252
- Jan 2029Primary completion: phase 2 study in PemphigusNCT04422912
- Jul 2029Primary completion: phase 3 study in Scleroderma, SystemicNCT06328777
- Sep 2029Primary completion: phase 2 study in Myasthenia GravisNCT06359041
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19, coupled to a ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07006805Multiple Sclerosis, Chronic Progressive | 2 | Withdrawn | Sep 2028 | 0 |
| NCT06359041Myasthenia Gravis · United States | 2 | Recruiting | Sep 2029 | 24 |
| NCT06328777Scleroderma, Systemic · United States | 3 | Recruiting | Jul 2029 | 37 |
| NCT06154252Myositis · United States, Germany, Italy and more | 3 | Recruiting | Jul 2028 | 74 |
| NCT06121297Lupus Erythematosus, Systemic · United States, Canada, Spain | 2 | Recruiting | Dec 2029 | 28 |
| NCT04422912Pemphigus · United States | 2 | Recruiting | Jan 2029 | 40 |
How it is read
Names in the registry
- “CABA-201”, 8 entries
- “CABA-201 following preconditioning with fludarabine and cyclophosphamide”, 1 entry
Conditions, from the studies’ own filings
- Dermatomyositis, 1 study
- Myasthenia Gravis, 1 study
- Scleroderma, Systemic, 1 study
- Pemphigus, 1 study
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.